The FDA recently approved Imdelltra (tarlatamab-dlle) for extensive-stage SCLC, showing a 44% tumor shrinkage rate in relapsed or treatment-resistant cases.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.